SCHEMBL3432034

SCHEMBL3432034

CS(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3nccs3)c3ccccc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
RECQL P46063 1/20 0.51
MAPT P10636 1/20 0.50
LMNA P02545 2/20 0.48
MAPK1 P28482 1/20 0.48
MCL1 Q07820 1/20 0.47
GCK P35557 2/20 0.46
PTGER4 P35408 4/20 0.46
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
KDM4E B2RXH2 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
POLB P06746 1/20 0.45
CNR1 P21554 1/20 0.44
METAP2 P50579 1/20 0.43
METAP1 P53582 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17038813 0.88 PTGER4 (0.55) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL30695024 0.88 PTGER4 (0.55) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL3755581 0.87 KMT2A (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2RECQL
SCHEMBL3428278 0.84 NPC1 (0.55) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3429672 0.84 ATR (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3755332 0.84 KDM4E (0.54) KMT2AMEN1MAPK1MCL1PTGER4
SCHEMBL3432112 0.83 ATR (0.49) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3428395 0.83 PTGER4 (0.54) KMT2AMEN1MCL1PTGER4KDM4E
SCHEMBL1607367 0.81 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3430198 0.81 KDM4E (0.51) KMT2AMEN1MAPK1MCL1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 KMT2A 2516/4885MEN1 3958/4885ALDH1A1 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.